Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma : a multicenter GELTAMO/FIL study
García-Sancho, Alejandro Martín (Hospital Universitario de Salamanca)
Bellei, Monica (Fondazione Italiana Linfomi (FIL) Onlus, Modena, Italy)
López-Parra, Miriam (Instituto de Investigación Biomédica de Salamanca)
Gritti, Giuseppe (, ASST Papa Giovanni XXIII, Bergamo, Italy)
Cortés, María (Department of Statistics, Hospital Universitario de Salamanca / IBSAL, Salamanca, Spain)
Novelli, Silvana (Institut d'Investigació Biomèdica Sant Pau)
Panizo, Carlos (Clínica Universidad de Navarra)
Petrucci, Luigi (Sapienza University)
Gutiérrez, Antonio (Hospital Universitari Son Espases (Palma de Mallorca, Balears))
Dlouhy, Ivan (Hospital Clínic i Provincial de Barcelona)
Bastos, Mariana (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM))
Sancho, Juan M. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Ramírez, María J. (Hematology Department, Hospital de Especialidades de Jerez de la Frontera, Cádiz, Spain)
Moraleda, José M. (Hospital Clínico Universitario Virgen de la Arrixaca (El Palmar, Múrcia))
Carrillo, Estrella (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Jiménez-Ubieto, Ana I. (Hospital Universitario 12 de Octubre (Madrid))
Jarque, Isidro (Instituto de Investigación Sanitaria La Fe)
Orsucci, Lorella (Candiolo Cancer Institute)
García-Torres, Estefanía (Hospital Universitario Reina Sofía (Còrdova, Espanya))
Montalbán, Carlos (Department of Translational Research, MD Anderson Cancer Center, Madrid, Spain)
Dodero, Anna (Division of Hematology and Bone Marrow Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy)
Arranz, Reyes (Hospital Universitario de la Princesa (Madrid))
De las Heras, Natalia (Department of Hematology, Complejo Hospitalario de León, León, Spain)
Pascual, María J. (Hospital Regional Universitario de Málaga)
López-Jiménez, Javier (Hospital Universitario Ramón y Cajal (Madrid))
Spina, Michelle (Division of Medical Oncology and Immune-related Tumors, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy)
Re, Alessandro (Division of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy)
de Villambrosia, Sonia González (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))
Bobillo, Sabela (Vall d'Hebron Institut d'Oncologia)
Federico, Massimo (University of Modena and Reggio Emilia)
Caballero, Dolores (Instituto de Investigación Biomédica de Salamanca)
Universitat Autònoma de Barcelona

Fecha:	2022
Resumen:	Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of rare lymphoid malignancies that mostly have poor prognoses with currently available treatments. Upfront consolidation with autologous stem cell transplantation (ASCT) is frequently carried out, but its efficacy has never been investigated in randomized trials. We designed a multicenter, international, retrospective study with the main objective of comparing progression-free survival and overall survival of patients with PTCL who underwent ASCT in complete remission (CR) after first-line chemotherapy with a control group who did not undergo ASCT. From the initial population of 286 registered patients, 174 patients with PTCL other than anaplastic large cell lymphoma, ALK-positive, deemed fit for ASCT at the time of diagnosis, and who were in CR or uncertain CR after induction therapy (CR1) were included in our analysis. one hundred and three patients underwent ASCT, whereas 71 did not, in most cases (n=53) because the physician decided against it. With a median follow-up of 65. 5 months, progression-free survival was significantly better in the transplanted patients than in the non-transplanted group: 63% versus 48% at 5 years (P =0. 042). Overall survival was significantly longer for ASCT patients in the subgroup with advanced stage at diagnosis (5-year overall survival: 70% vs. 50%, P =0. 028). In the multivariate analysis, first-line ASCT was associated with significantly prolonged progression-free survival (HR=0. 57, 95% CI: 0. 35-0. 93) and overall survival (HR=0. 57, 95% CI: 0. 33-0. 99). In conclusion, our study supports the use of ASCT as a consolidation strategy for patients with PTCL in CR1. These results should be confirmed in a prospective randomized study.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Publicado en:	Haematologica, Vol. 107 (march 2022) , p. 2675-2684, ISSN 1592-8721

DOI: 10.3324/haematol.2021.279426
PMID: 35320921

10 p, 578.0 KB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados